Gram-negative bacterial lipopolysaccharide and outer membrane (LPS/OM)

The Gram-negative bacterial outer membrane (OM) is a specialized asymmetric lipid bilayer that serves as a formidable permeability barrier against toxic compounds, including many antibiotics (NIH, 2023). The outer leaflet of this membrane is primarily composed of lipopolysaccharide (LPS), a complex glycolipid essential for the viability of most Gram-negative species (Nature, 2024). LPS consists of three distinct regions: the hydrophobic Lipid A anchor, a core oligosaccharide, and a distal O-antigen polysaccharide (PubMed, 2022). Beyond its structural role, LPS is a potent endotoxin that triggers the host's innate immune system via the TLR4/MD-2 receptor complex, potentially leading to systemic inflammation (StatPearls, 2023). Therapeutic targeting of the LPS/OM involves disrupting its integrity, as seen with polymyxin antibiotics which bind to Lipid A and displace stabilizing divalent cations (NCBI, 2023). Recent drug development has shifted toward inhibiting the Lipopolysaccharide Transport (Lpt) pathway, which is responsible for trafficking LPS from the inner membrane to the cell surface (Nature, 2024). However, targeting this structure remains challenging due to the risk of nephrotoxicity and the potential for massive endotoxin release during bacterial lysis (PubMed, 2021).

Other names

LipopolysaccharideEndotoxinLPS layerGram-negative outer membraneLipid A

Drugs targeting this structure typically act by binding to the negatively charged phosphate groups of Lipid A, displacing divalent cations (Mg2+ and Ca2+) that stabilize the membrane, which leads to increased permeability and cell death (StatPearls, 2023). Newer therapeutic agents, such as macrocyclic peptides, inhibit the Lpt (Lipopolysaccharide transport) protein machinery, specifically the LptB2FGC complex or LptD, preventing the assembly of the LPS layer (Nature, 2024).